NCT07160322Recruiting
Refractory Breathlessness in COPD
Prognosis and Clinical Outcomes of Refractory Dyspnea in Chronic Obstructive Pulmonary Disease: Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 8 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate the prognosis and clinical outcomes of patients with chronic obstructive pulmonary disease (COPD) who continue to experience refractory dyspnea despite treatment with long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA). The research will prospectively follow a cohort of patients to identify clinical factors, lung function parameters, imaging features, and cardiovascular indicators associated with poor treatment response. By comparing these patients with those who show symptom improvement, the study seeks to determine predictors of exacerbations, lung function decline, and mortality. Findings are expected to guide the development of targeted strategies to improve the management of refractory dyspnea in COPD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 730 (estimated)
- First submitted
- 20 Jul 2025
- Start date
- 11 Apr 2024
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Seoul National University
- Diseases
- COPD
- NCT number
- NCT07160322
What you commit to
- Study type: Observational
- Planned participants: 730
- From 11 Apr 2024 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Poor adherence to LABA/LAMA therapy (medication possession rate \< 50%) or refusal of treatment.
- Presence of severe comorbid conditions expected to significantly affect prognosis, including:
- End-stage diseases with life expectancy \< 1 year.
- Terminal malignancies receiving hospice or palliative care.
Other illness
- Any condition that, in the opinion of the investigator, would interfere with study participation or data reliability.
Other
- Inability or unwillingness to comply with scheduled visits, examinations, or follow-up procedures.
Who the study is looking for
- Adults (≥ 18 years) diagnosed with chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 criteria:
- Presence of COPD risk factors (e.g., smoking history, occupational exposure, genetic predisposition).
- Typical symptoms such as dyspnea, cough, or sputum production.
- Post-bronchodilator FEV1/FVC \< 0.70.
- Regular outpatient follow-up at the respiratory clinic.
- Received LABA/LAMA combination therapy for at least 3 months prior to enrollment.
- Ability and willingness to provide written informed consent.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.